

Irene M Ghobrial

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1130387/irene-m-ghobrial-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284
papers

6,277
citations

41
h-index

75
g-index

318
ext. papers

8,091
ext. citations

5
avg, IF

5.87
L-index

#	Paper	IF	Citations
284	Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	10
283	Mass cytometry staining for human bone marrow clinical samples.. <i>STAR Protocols</i> , 2022 , 3, 101163	1.4	0
282	Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.. <i>Cancer Cell</i> , 2021 ,	24.3	3
281	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4082-4082	2.2	
280	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1659-1659	2.2	
279	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4782-4782	2.2	
278	A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2749-2749	2.2	0
277	Single Cell Characterization of Myeloma and Its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis. <i>Blood</i> , 2021 , 138, 2219-2219	2.2	
276	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3044-3044	2.2	1
275	Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2021 , 138, 504-504	2.2	
274	Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes. <i>Blood</i> , 2021 , 138, 145-145	2.2	1
273	Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology. <i>Blood</i> , 2021 , 138, 78-78	2.2	1
272	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1649-1649	2.2	1
271	Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2021 , 138, 1091-1091	2.2	0
270	Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenström Macroglobulinemia. <i>Blood</i> , 2021 , 138, 2678-2678	2.2	0
269	Single-cell RNA sequencing: one step closer to the clinic. <i>Nature Medicine</i> , 2021 , 27, 375-376	50.5	5
268	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , 2021 , 2, 338-353	7	1

267	Inflammatory stromal cells in the myeloma microenvironment. <i>Nature Immunology</i> , 2021 , 22, 677-678	19.1	0
266	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12082-12082	2.2	
265	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , 2021 , 138, 1535-1539	2.2	7
264	Progression signature underlies clonal evolution and dissemination of multiple myeloma. <i>Blood</i> , 2021 , 137, 2360-2372	2.2	9
263	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021 , 39, 565-575	2.2	40
262	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
261	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 807-816		1
260	The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1283-1289	4	22
259	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. <i>Blood</i> , 2020 , 135, 1912-1915	2.2	195
258	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
257	Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. <i>Cancers</i> , 2020 , 12,	6.6	9
256	Intensification and consolidation therapy in multiple myeloma in the current era. <i>Lancet Haematology</i> , 2020 , 7, e427-e429	14.6	0
255	Genome instability in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 2887-2897	10.7	22
254	Bone marrow niches in haematological malignancies. <i>Nature Reviews Cancer</i> , 2020 , 20, 285-298	31.3	134
253	Prediagnosis dietary pattern and survival in patients with multiple myeloma. <i>International Journal of Cancer</i> , 2020 , 147, 1823-1830	7.5	10
252	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1198-1208	2.2	40
251	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020 , 1, 493-506	15.4	73
250	A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts. <i>Blood</i> , 2020 , 136, 1-2	2.2	

249	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. <i>Blood</i> , 2020 , 136, 33-33	2.2	
248	Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation. <i>Blood</i> , 2020 , 136, 1-2	2.2	1
247	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2380-2389	2.2	46
246	Dissecting racial disparities in multiple myeloma. <i>Blood Cancer Journal</i> , 2020 , 10, 19	7	34
245	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 344-353	12.9	39
244	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. <i>Leukemia Research</i> , 2020 , 98, 106459	2.7	9
243	Mapping the Degradable Kinome Provides a Resource for Expedited Degradation Development. <i>Cell</i> , 2020 , 183, 1714-1731.e10	56.2	58
242	Pro-organic radical contrast agents ("pro-ORCAs") for real-time MRI of pro-drug activation in biological systems. <i>Polymer Chemistry</i> , 2020 , 11, 4768-4779	4.9	10
241	BELLINI: a renaissance for an era of precision therapy in multiple myeloma. <i>Lancet Oncology</i> , 2020 , 21, 1547-1549	21.7	1
240	Clinical Controversies in the Management of Smoldering Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-6	7.1	2
239	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 1244-1253	7.1	24
238	Mitochondrial metabolism promotes adaptation to proteotoxic stress. <i>Nature Chemical Biology</i> , 2019 , 15, 681-689	11.7	62
237	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019 , 25, 4907-4916	12.9	25
236	Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz025	4.6	15
235	Monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2019 , 133, 2484-2494	2.2	34
234	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 332-344	2	13
233	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019 , 33, 266-270	10.7	8
232	Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo. <i>Journal of Biomedical Optics</i> , 2019 , 24, 1-11	3.5	11

231	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019 , 134, 4172-4172	2.2	4
230	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3178-3178	2.2	8
229	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. <i>Blood</i> , 2019 , 134, 1898-1898	2.2	4
228	Immunotherapy for hematological malignancies. <i>Journal of Life Sciences (Westlake Village, Calif)</i> , 2019 , 1, 46-52	1.9	3
227	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. <i>Blood</i> , 2019 , 134, 4341-4341	2.2	4
226	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche. <i>Blood</i> , 2019 , 134, 507-507	2.2	
225	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. <i>Blood</i> , 2019 , 134, 853-853	2.2	
224	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019 , 94, E146-E149	7.1	7
223	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 995-1002	7.8	5
222	Bone marrow niche in multiple myeloma and its precursor states.. <i>HemaSphere</i> , 2019 , 3,	0.3	1
221	Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. <i>Nanoscale</i> , 2019 , 11, 20485-20496	7.7	14
220	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019 , 25, 478-486	12.9	19
219	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1454-1463	6.1	49
218	Platelets Enhance Multiple Myeloma Progression via IL-1 β Upregulation. <i>Clinical Cancer Research</i> , 2018 , 24, 2430-2439	12.9	26
217	The bone-marrow niche in MDS and MGUS: implications for AML and MM. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 219-233	19.4	81
216	Current use of monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 181, 447-459	4.5	28
215	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 182, 222-230	4.5	70
214	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. <i>Leukemia</i> , 2018 , 32, 1739-1750	10.7	22

213	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2487-2499	15.9	48
212	Aspirin Use and Survival in Multiple Myeloma Patients. <i>Blood</i> , 2018 , 132, 3250-3250	2.2	2
211	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
210	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. <i>Blood</i> , 2018 , 132, 2603-2603	2.2	1
209	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 804-804	2.2	14
208	New Approaches to Multiple Myeloma. <i>European Oncology and Haematology</i> , 2018 , 14, 18	0.1	
207	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3263-3263	2.2	
206	Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule. <i>Blood</i> , 2018 , 132, 2024-2024	2.2	
205	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. <i>Blood</i> , 2018 , 132, 55-55	2.2	
204	Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). <i>Blood</i> , 2018 , 132, 5664-5664	2.2	
203	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , 2018 , 132, 1981-1981	2.2	0
202	In Vivo Modeling of Clonal Competition Using CRISPR-Based Gene Editing Reveals Novel Fitness Variables in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 57-57	2.2	
201	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018 , 13, e0204589	3.7	13
200	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenström macroglobulinemia patients. <i>Blood</i> , 2018 , 132, 2608-2612	2.2	19
199	Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging. <i>ACS Nano</i> , 2018 , 12, 11343-11354	16.7	43
198	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018 , 2, 1272-1276	7.8	4
197	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017 , 92, 448-453	7.1	20
196	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , 2017 , 129, 2429-2436	2.2	161

195	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. <i>British Journal of Haematology</i> , 2017 , 176, 929-938	4.5	15
194	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2017 , 177, 717-725	4.5	44
193	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017 , 92, E138-E145	7.1	2
192	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	36
191	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017 , 19, 218-224	6.6	67
190	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017 , 92, 746-751	7.1	21
189	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 548-560	7.1	16
188	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. <i>Current Osteoporosis Reports</i> , 2017 , 15, 499-506	5.4	18
187	Genomic complexity of multiple myeloma and its clinical implications. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 100-113	19.4	267
186	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenström Macroglobulinemia (WMCTG 09-214). <i>Clinical Cancer Research</i> , 2017 , 23, 2400-2404	12.9	17
185	Multiple Myeloma and the Immune Microenvironment. <i>Current Cancer Drug Targets</i> , 2017 , 17, 806-818	2.8	35
184	Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. <i>JCI Insight</i> , 2017 , 2,	9.9	17
183	The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. <i>Oncotarget</i> , 2017 , 8, 35435-35444	3.3	3
182	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2699-701	1.9	3
181	Targeting SDF-1 in multiple myeloma tumor microenvironment. <i>Cancer Letters</i> , 2016 , 380, 315-8	9.9	23
180	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. <i>Cancer Research</i> , 2016 , 76, 463-71	10.1	31
179	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 1137-1137	2.2	2
178	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 197-197	2.2	7

177	Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). <i>Blood</i> , 2016 , 128, 4487-4487	2.2	2
176	Exosomes in Tumor Angiogenesis. <i>Methods in Molecular Biology</i> , 2016 , 1464, 25-34	1.4	24
175	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 237-237	2.2	
174	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. <i>Blood</i> , 2016 , 128, 4169-4169	2.2	
173	In Vivo Analysis of Clonal Evolution of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 799-799	2.2	
172	Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia. <i>Blood</i> , 2016 , 128, 2940-2940	2.2	
171	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e400-6	7.1	1
170	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016 , 172, 709-15	4.5	60
169	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016 , 91, 400-5	7.1	73
168	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E8425-E8432	11.5	45
167	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016 , 127, 2598-606	2.2	16
166	Epigenomics in Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 156-160	4.2	1
165	Epigenetics in Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016 , 169, 35-49	3.5	6
164	Genomic Aberrations in Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016 , 169, 23-34	3.5	10
163	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 2015 , 90, E122-3	7.1	7
162	The cancer glycome: carbohydrates as mediators of metastasis. <i>Blood Reviews</i> , 2015 , 29, 269-79	11.1	73
161	Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. <i>Bone</i> , 2015 , 75, 161-9	4.7	46
160	Ibrutinib in previously treated Waldenström's macroglobulinemia. <i>New England Journal of Medicine</i> , 2015 , 372, 1430-40	59.2	617

159	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. <i>Journal of Molecular Diagnostics</i> , 2015 , 17, 669-78	5.1	30
158	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , 2015 , 169, 843-50	4.5	42
157	Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm. <i>Oncologist</i> , 2015 , 20, 1077-83	5.7	41
156	Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma. <i>Palliative and Supportive Care</i> , 2015 , 13, 829-38	2.5	4
155	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015 , 169, 851-8	4.5	44
154	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015 , 12, 622-35	10.6	94
153	Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia. <i>Molecular Cancer Research</i> , 2015 , 13, 263-72	6.6	21
152	Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden. <i>Blood</i> , 2015 , 126, 119-119	2.2	13
151	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenström's Macroglobulinemia. <i>Blood</i> , 2015 , 126, 1833-1833	2.2	16
150	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 23-23	2.2	10
149	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4217-4217	2.2	7
148	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4256-4256	2.2	4
147	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. <i>Blood</i> , 2015 , 126, 502-502	2.2	4
146	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 1755-1755	2.2	
145	A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish. <i>Blood</i> , 2015 , 126, 915-915	2.2	
144	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 1770-1770		
143	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 1793-1793	2.2	0
142	Regulation of microRNAs in cancer metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1845, 255-65	11.2	109

141	Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. <i>Cytokine</i> , 2014 , 69, 294-7	4	11
140	Engineered nanomedicine for myeloma and bone microenvironment targeting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10287-92	11.5	204
139	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. <i>Blood</i> , 2014 , 124, 1905-14	2.2	27
138	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. <i>Blood</i> , 2014 , 124, 1765-76	2.2	80
137	Pyk2 promotes tumor progression in multiple myeloma. <i>Blood</i> , 2014 , 124, 2675-86	2.2	48
136	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. <i>Blood</i> , 2014 , 123, 4120-31	2.2	150
135	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014 , 124, 1404-11	2.2	107
134	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood</i> , 2014 , 124, 503-10	2.2	127
133	Global epigenetic regulation of microRNAs in multiple myeloma. <i>PLoS ONE</i> , 2014 , 9, e110973	3.7	28
132	How I treat smoldering multiple myeloma. <i>Blood</i> , 2014 , 124, 3380-8	2.2	31
131	SDF-1 inhibition targets the bone marrow niche for cancer therapy. <i>Cell Reports</i> , 2014 , 9, 118-128	10.6	93
130	Team work matters: dual inhibition puts non-hodgkin lymphoma under siege. <i>Clinical Cancer Research</i> , 2014 , 20, 5863-5	12.9	1
129	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3955-61	12.9	27
128	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. <i>Blood</i> , 2014 , 124, 3250-9	2.2	98
127	Role of endothelial progenitor cells in cancer progression. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 26-39	11.2	60
126	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenström Macroglobulinemia. <i>Blood</i> , 2014 , 124, 3081-3081	2.2	3
125	Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3370-3370		1
124	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. <i>Blood</i> , 2014 , 124, 34-34	2.2	21

123	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3431-3431	2.2	4
122	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3483-3483	2.2	13
121	Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. <i>Current Cancer Therapy Reviews</i> , 2014 , 10, 70-79	0.4	26
120	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. <i>Blood</i> , 2014 , 124, 2051-2051	2.2	
119	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 5777-5777	2.2	2
118	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. <i>Blood</i> , 2014 , 124, 3430-3430	2.2	
117	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. <i>Blood</i> , 2014 , 124, 2101-2101	2.2	
116	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2056-2056	2.2	
115	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. <i>British Journal of Haematology</i> , 2013 , 160, 171-6	4.5	173
114	Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. <i>Blood</i> , 2013 , 121, 1296-303	2.2	45
113	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1947-1947	2.2	4
112	A Prospective Multicenter Study Of The Bruton Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia. <i>Blood</i> , 2013 , 122, 251-251	2.2	29
111	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenström Macroglobulinemia Biology. <i>Blood</i> , 2013 , 122, 272-272	2.2	3
110	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenström's Macroglobulinemia. <i>Blood</i> , 2013 , 122, 4402-4402	2.2	3
109	Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenström Macroglobulinemia. <i>Blood</i> , 2013 , 122, 5090-5090	2.2	10
108	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. <i>Blood</i> , 2013 , 122, 680-680	2.2	3
107	Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenström Macroglobulinemia. <i>Blood</i> , 2013 , 122, 757-757	2.2	5
106	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/βCatenin Signaling Pathway. <i>Blood</i> , 2013 , 122, 3094-3094	2.2	

105	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 121-121	2.2	
104	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 3086-3086	2.2	
103	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3159-3159	2.2	
102	Extramedullary Disease In Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013 , 122, 1773-1773	2.2	
101	A Case-Control Epidemiological Study Of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2013 , 122, 1713-1713	2.2	
100	Hypoxia Induces Drug Resistance In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1852-1852	2.2	0
99	Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3751-3751	2.2	
98	Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3093-3093	2.2	
97	Myeloma as a model for the process of metastasis: implications for therapy. <i>Blood</i> , 2012 , 120, 20-30	2.2	139
96	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. <i>Blood</i> , 2012 , 119, 5782-94	2.2	234
95	Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. <i>Clinical Cancer Research</i> , 2012 , 18, 342-9	12.9	101
94	Are you sure this is Waldenstrom macroglobulinemia?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 586-94	3.1	16
93	Are you sure this is Waldenstrom's macroglobulinemia?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 586-594	3.1	27
92	In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. <i>Blood</i> , 2012 , 120, 440-440	2.2	1
91	Multiple Myeloma-Derived Bone-Marrow Mesenchymal Stem Cells: Microrna-, Gene Expression-Profilng and Functional Characterization. <i>Blood</i> , 2012 , 120, 1837-1837	2.2	
90	CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NF- κ B While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1835-1835	2.2	
89	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 3944-3944	2.2	
88	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 570-570	2.2	

87	Targeting the bone marrow in Waldenstrom macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11 Suppl 1, S65-9	2	5
86	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. <i>Lancet Oncology, The</i> , 2011 , 12, 263-72	21.7	72
85	The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1844-1844	2.2	2
84	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1874-1874	2.2	1
83	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2705-2705	2.2	1
82	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2706-2706	2.2	1
81	Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2951-2951	2.2	11
80	Incidence of Peripheral Neuropathy in Waldenstrom Macroglobulinemia Patients At Diagnosis,. <i>Blood</i> , 2011 , 118, 3692-3692	2.2	1
79	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011 , 118, 3966-3966	2.2	1
78	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 625-625	2.2	2
77	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. <i>Blood</i> , 2011 , 118, 471-471	2.2	
76	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. <i>Blood</i> , 2011 , 118, 1409-1409	2.2	
75	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , 2011 , 118, 815-815	2.2	
74	The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1804-1804	2.2	
73	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 4134-4134	2.2	
72	L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to Enhanced Sensitivity to Bortezomib. <i>Blood</i> , 2011 , 118, 887-887	2.2	
71	Role of TORC1 and TORC2 in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1815-1815	2.2	
70	The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2713-2713	2.2	

69	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. <i>Blood</i> , 2011 , 118, 3669-3669	2.2	
68	Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 3934-3934	2.2	
67	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 2728-2728	2.2	
66	Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2424-2424	2.2	
65	Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment. <i>Blood</i> , 2010 , 116, 142-142	2.2	2
64	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1943-1943	2.2	2
63	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. <i>Blood</i> , 2010 , 116, 3051-3051	2.2	3
62	The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010 , 116, 3095-3095	2.2	1
61	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010 , 116, 3952-3952	2.2	6
60	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. <i>Blood</i> , 2010 , 116, 453-453	2.2	1
59	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , 2010 , 116, 990-990	2.2	5
58	Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma.. <i>Blood</i> , 2010 , 116, 3622-3622		
57	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. <i>Blood</i> , 2010 , 116, 4035-4035	2.2	
56	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. <i>Blood</i> , 2010 , 116, 456-456	2.2	
55	Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells. <i>Blood</i> , 2010 , 116, 2958-2958	2.2	
54	Hevylite [®] , a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010 , 116, 5076-5076	2.2	1
53	LNA Anti-Microrna-155: a Novel Therapeutic Strategy In Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 4914-4914	2.2	
52	Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010 , 116, 3620-3620		

51	The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010 , 116, 4153-4153	2.2	
50	Finding the right academic job. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 729-33	3.1	4
49	Novel therapeutic agents in Waldenström's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 84-6		4
48	ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 587-9	3.1	11
47	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. <i>Blood</i> , 2009 , 113, 4341-51	2.2	354
46	MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.. <i>Blood</i> , 2009 , 114, 1785-1785	2.2	1
45	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009 , 114, 1852-1852	2.2	3
44	RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2009 , 114, 3732-3732	2.2	2
43	Role of Selectins in the Pathogenesis of Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 951-951	2.2	1
42	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009 , 114, 2727-2727	2.2	
41	Primary Waldenstrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease.. <i>Blood</i> , 2009 , 114, 3843-3843	2.2	
40	Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2009 , 114, 3952-3952	2.2	
39	Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells.. <i>Blood</i> , 2009 , 114, 1825-1825	2.2	
38	Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglobulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.. <i>Blood</i> , 2009 , 114, 2935-2935	2.2	
37	The Role of FGFR in the Progression of Waldenstrom's Macroglobulinemia and the Effect of Its Inhibition by TKI-258.. <i>Blood</i> , 2009 , 114, 3737-3737	2.2	
36	The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment.. <i>Blood</i> , 2009 , 114, 1826-1826	2.2	
35	Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2009 , 114, 4911-4911	2.2	
34	Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2009 , 114, 4916-4916		

33	Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 421-421	2.2	
32	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009 , 114, 3752-3752	2.2	1
31	PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2009 , 114, 1937-1937		
30	Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 748-748	2.2	
29	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , 2008 , 112, 1011-1011	2.2	1
28	Phase I Trial of CCI-779 (Temsirrolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3696-3696	2.2	10
27	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008 , 112, 832-832	2.2	6
26	Identification of An Atypical Paraprotein with Inconsistent M-Spike Quantitation in Four Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2008 , 112, 5145-5145	2.2	
25	The Effect of Insulin-Like Growth Factor 1 on Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008 , 112, 4994-4994		
24	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. <i>Blood</i> , 2008 , 112, 2737-2737	2.2	
23	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 155-63	3.7	9
22	Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007 , 110, 1486-1486	2.2	1
21	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007 , 110, 1516-1516	2.2	2
20	In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.. <i>Blood</i> , 2007 , 110, 2501-2501	2.2	3
19	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4493-4493	2.2	1
18	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4496-4496	2.2	2
17	Targeting NF- κ B by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007 , 110, 2512-2512	2.2	
16	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4494-4494	2.2	

15	The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2007 , 110, 2617-2617	2.2	
14	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2007 , 110, 1383-1383	2.2	
13	Regulation of the New CXCR7 Receptor in Plasma Cell Dyscrasias.. <i>Blood</i> , 2007 , 110, 3527-3527	2.2	
12	Serum Free Light Chain in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2006 , 108, 2420-2420	2.2	3
11	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2006 , 108, 2496-2496	2.2	2
10	Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2006 , 108, 2517-2517	2.2	3
9	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. <i>Blood</i> , 2006 , 108, 2765-2765	2.2	6
8	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006 , 108, 3460-3460	2.2	1
7	Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom Macroglobulinemia, the Role of the ERK and PKC Pathways.. <i>Blood</i> , 2006 , 108, 2416-2416	2.2	
6	Imatinib Mesylate (Gleevec) Is Active in Relapsed/Refractory Waldenstrom Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.. <i>Blood</i> , 2006 , 108, 2484-2484	2.2	
5	The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2006 , 108, 2418-2418	2.2	
4	A Novel Real-Time In Vivo Homing Model of Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 242-242	2.2	
3	Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2006 , 108, 2488-2488	2.2	1
2	Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders (PTLD), BCL2 Is a Poor Prognostic Marker in PTLD.. <i>Blood</i> , 2006 , 108, 2035-2035	2.2	
1	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. <i>Blood Cancer Discovery</i> , OF1-OF12	7	2